NASDAQ:AGLE - Aeglea BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.67
  • Forecasted Upside: 66.01 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.63
▲ +0.19 (2.55%)
1 month | 3 months | 12 months
Get New Aeglea BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGLE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGLE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.67
▲ +66.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $12.67, with a high forecast of $15.00 and a low forecast of $11.00. The average price target represents a 66.01% upside from the last price of $7.63.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Aeglea BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020HC WainwrightReiterated RatingBuy$17.00 ➝ $15.00High
i
10/23/2020Lifesci CapitalReiterated RatingOutperformMedium
i
Rating by S. Slutsky at Lifesci Capital
9/16/2020HC WainwrightReiterated RatingBuy$17.00Medium
i
8/10/2020Needham & Company LLCReiterated RatingBuy$11.00High
i
Rating by Chad Messer at Needham & Company LLC
5/26/2020Needham & Company LLCInitiated CoverageBuy$11.00Low
i
Rating by Chad Messer at Needham & Company LLC
5/8/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $17.00Low
i
5/7/2020Needham & Company LLCLower Price TargetBuy$14.00 ➝ $11.00High
i
Rating by Chad Messer at Needham & Company LLC
5/4/2020Piper SandlerInitiated CoverageOverweight$12.00Medium
i
4/30/2020HC WainwrightLower Price TargetBuy$24.00 ➝ $18.00Low
i
4/8/2020Needham & Company LLCReiterated RatingBuy$14.00High
i
Rating by Chad Messer at Needham & Company LLC
2/26/2020Needham & Company LLCReiterated RatingBuy ➝ Average$14.00High
i
2/25/2020HC WainwrightBoost Price TargetBuy$20.00 ➝ $24.00High
i
6/3/2019HC WainwrightReiterated RatingBuy$20.00Low
i
Rating by E. White at HC Wainwright
5/21/2019HC WainwrightInitiated CoverageBuy$20.00 ➝ $20.00High
i
Rating by E. White at HC Wainwright
3/21/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$14.00Medium
i
9/4/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
6/14/2018BMO Capital MarketsInitiated CoverageOutperform$21.00High
i
4/24/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$37.00High
i
4/13/2018Needham & Company LLCBoost Price TargetBuy$20.00High
i
3/14/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$8.00 ➝ $12.00High
i
3/14/2018BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$18.00Medium
i
11/10/2016BMO Capital MarketsReiterated RatingBuy$19.00N/A
i
5/9/2016Needham & Company LLCInitiated CoverageBuy$18.00N/A
i
5/2/2016UBS GroupInitiated CoverageBuy$12.00N/A
i
5/2/2016BMO Capital MarketsInitiated CoverageOutperform$19.00N/A
i
5/2/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
(Data available from 1/22/2016 forward)
Aeglea BioTherapeutics logo
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $7.63
$7.22
$7.66

50 Day Range

MA: $8.19
$7.44
$9.09

52 Week Range

Now: $7.63
$3.50
$11.38

Volume

345,063 shs

Average Volume

207,933 shs

Market Capitalization

$365.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeglea BioTherapeutics?

The following sell-side analysts have issued reports on Aeglea BioTherapeutics in the last year: HC Wainwright, Lifesci Capital, Needham & Company LLC, Piper Sandler, and Zacks Investment Research.

What is the current price target for Aeglea BioTherapeutics?

3 Wall Street analysts have set twelve-month price targets for Aeglea BioTherapeutics in the last year. Their average twelve-month price target is $12.67, suggesting a possible upside of 66.0%. HC Wainwright has the highest price target set, predicting AGLE will reach $15.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $11.00 for Aeglea BioTherapeutics in the next year.

What is the current consensus analyst rating for Aeglea BioTherapeutics?

Aeglea BioTherapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGLE will outperform the market and that investors should add to their positions of Aeglea BioTherapeutics.

What other companies compete with Aeglea BioTherapeutics?

How do I contact Aeglea BioTherapeutics' investor relations team?

Aeglea BioTherapeutics' physical mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company's listed phone number is 512-942-2935 and its investor relations email address is [email protected] The official website for Aeglea BioTherapeutics is www.aegleabio.com.